Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA (NYXH) is a medical technology company that develops and commercializes neuromodulation-based therapies for obstructive sleep apnea (OSA), centered on its Genio hypoglossal neurostimulation system. The Nyxoah news feed on Stock Titan brings together company-issued announcements, regulatory disclosures and market updates that reflect how the business is progressing in its target markets.
Investors following Nyxoah’s news can track updates on U.S. and European commercialization of the Genio system, including surgeon training, account activations and the completion of commercial implants. Company press releases describe milestones such as the commercial launch of Genio in new countries, early U.S. implant activity after FDA approval, and developments in reimbursement coverage with public and private payers.
Nyxoah also regularly reports on its financial position and capital markets activity. News items include quarterly financial and operating results, preliminary revenue updates, private placements, registered direct offerings and convertible bond financings, as well as information on voting rights, share capital and transparency notifications regarding significant shareholdings. These disclosures provide context on how the company funds its commercialization and research plans.
In addition, the news stream features regulatory and legal developments, such as FDA approval of the Genio system for a defined subset of adult OSA patients, CE mark expansions, and intellectual property litigation updates referenced in company filings. By reviewing the NYXH news page, readers can see how Nyxoah communicates progress on clinical, regulatory, commercial and financing fronts over time.
Nyxoah (NASDAQ: NYXH), a medical technology company focused on Obstructive Sleep Apnea (OSA) treatment, announced the expansion of its commercial presence in the Middle East. Following the first successful Genio® implant in Abu Dhabi in September 2025, the company has established new centers across Dubai, Kuwait, and Abu Dhabi.
The Genio® system, which is the only leadless, externally powered bilateral hypoglossal nerve stimulation system for treating moderate-to-severe OSA, is now available through partnerships with leading healthcare institutions in these regions. This expansion follows the company's initial Middle East launch earlier in 2025, targeting patients who cannot tolerate CPAP therapy.
["Geographic expansion into multiple Middle East markets", "Successful first Genio implant completed in Abu Dhabi", "Partnerships established with leading healthcare institutions in the region", "Entry into world-class healthcare systems with renowned Key Opinion Leaders"]Nyxoah (NASDAQ:NYXH) has filed a patent infringement lawsuit against Inspire Medical Systems in the United States District Court for the District of Delaware. The lawsuit alleges that Inspire's IV and V devices infringe on three of Nyxoah's U.S. patents (8,700,183, 9,415,215, and 9,415,216).
The Company is seeking injunctive relief and damages, while defending its proprietary Genio® system, which features bilateral stimulation, full body MRI compatibility, and an upgradable platform that eliminates the need for battery replacement surgery. CEO Olivier Taelman highlighted positive feedback from the first month of U.S. commercial launch of the Genio system for Obstructive Sleep Apnea (OSA) treatment.
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced receiving a transparency notification from Cochlear Limited and Cochlear Investments Pty Ltd following a passive threshold crossing. The notification reveals that Cochlear Investments Pty Ltd now holds 5,631,319 voting rights, representing 14.999% of total voting rights (37,544,782) as of August 29, 2025.
The change represents a passive downward crossing of the 15% threshold, with Cochlear Investments Pty Ltd's holding decreasing from 15.04% to 14.999%. Cochlear Investments Pty Ltd is a wholly owned subsidiary of Cochlear Limited, an Australian Securities Exchange-listed company with no controlling shareholder.
Nyxoah (NASDAQ: NYXH), a medical technology company focused on Obstructive Sleep Apnea (OSA) treatment, has announced its participation in four major healthcare investor conferences in September 2025.
The company will attend the Wells Fargo Healthcare Conference in Boston (Sept 3), Cantor Global Healthcare Conference in New York (Sept 4, 11:30-12:00 pm ET), Morgan Stanley Global Healthcare Conference in New York (Sept 9, 5:35-6:10 pm ET), and Baird's Global Healthcare Conference in New York (Sept 10). Live webcasts will be available on Nyxoah's Investor Relations website, and the company will conduct one-on-one meetings with institutional investors.
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has disclosed updated information regarding its voting rights and shares as required by Belgian law. The company reported a share capital of EUR 6,449,871.98 with 37,544,782 ordinary shares, each carrying one voting right. Additionally, there are 2,775,566 subscription rights not yet issued, excluding 493,057 subscription rights that were issued but not yet granted.
Nyxoah (NASDAQ:NYXH) has achieved a significant milestone with FDA approval of its Genio system, the first and only bilateral hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA) in the U.S. market. The company has initiated its commercial launch with strong Q2 2025 results, reporting revenue of €1.3 million, a 74% year-over-year increase.
The Genio system's approval was supported by the DREAM pivotal trial data, demonstrating 66.6% median AHI reduction in supine position and 71.0% reduction in non-supine position. The company's cash position stands at €43.0 million as of June 30, 2025, with an additional €27.5 million available through a term debt facility.
Operating loss increased to €19.9 million in Q2 2025, primarily due to expanded commercialization efforts and R&D activities.
Nyxoah (NASDAQ: NYXH), a medical technology company focused on Obstructive Sleep Apnea (OSA) treatment, has announced preliminary Q2 2025 results. The company achieved revenue of €1.3 million, marking a 73% year-over-year increase. Operating expenses rose 50% to €20.7 million.
Key developments include FDA approval of the Genio® system for moderate to severe OSA patients with AHI between 15 and 65. The company maintains €43.0 million in cash and equivalents, with access to an additional €27.5 million in debt facility. Nyxoah plans to conclude ACCCESS trial enrollment early while maintaining the study's co-primary endpoints. The company faces a patent infringement lawsuit from Inspire Medical Systems and is reorganizing its R&D operations from Israel to the U.S. and Belgium.
Nyxoah (NASDAQ: NYXH) has received FDA approval for its Genio® system, a breakthrough treatment for moderate to severe Obstructive Sleep Apnea (OSA). The approval covers patients with an Apnea-Hypopnea Index (AHI) between 15 and 65.
The Genio system represents a novel approach to hypoglossal nerve stimulation, featuring bilateral stimulation and a unique leadless design that is MRI compatible. The system's efficacy was demonstrated in the DREAM pivotal trial, achieving a 63.5% AHI responder rate and an impressive 70.8% median AHI reduction.
Notably, the system showed consistent effectiveness across all sleeping positions, with a 66.6% median AHI reduction in supine position and 71.0% reduction in non-supine position. The company has officially launched its U.S. commercialization efforts.
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has disclosed updated information regarding its voting rights and shares as required by Belgian law. The company reported a share capital of EUR 6,432,066.28 with 37,441,140 ordinary shares, each carrying one voting right. Additionally, there are 2,793,941 subscription rights not yet issued, excluding 493,057 subscription rights that were issued but not yet granted.
Nyxoah (NASDAQ:NYXH), a company focused on developing innovative treatments for Obstructive Sleep Apnea (OSA) through neuromodulation, has scheduled its Q2 2025 earnings release for August 18, 2025.
The company will host a conference call with management on the same day at 10:30pm CET / 4:30pm ET. Investors can access the call through the company's Investor Relations webpage or via a direct webcast link. Those planning to ask questions during the call should register at least 10 minutes before the start time using a separate registration link.
A replay of the webcast will be made available shortly after the call concludes.